Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer
Andrew D Smith and John L Phillips*
Correspondence *Beth Israel Medical Center, Berger Department of Urology, 10 Union Square East, New York, NY 10003, USA
Email jlphillips@chpnet.org
Measuring PSA velocity to track prostatic pathophysiologic states is appealing for its simplicity, however, much debate continues as to its clinical value in the diagnosis and characterization of prostate cancer. Phillips and Smith discuss the significance of PSA velocity as a diagnostic measure.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.